Mancini Anthony 4
4 · Revolution Medicines, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) CCO Anthony Mancini Exercises Options, Sells Shares
What Happened
- Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised 37,450 stock options on March 25, 2026 by paying $33.62 per share (total exercise cost $1,259,069) and sold 37,450 shares the same day in multiple open‑market trades for aggregate proceeds of about $3,578,820. The Form 4 shows a related derivative line reported at $0 (conversion/settlement).
Key Details
- Transaction date: 2026-03-25; Form filed: 2026-03-26 (timely).
- Exercise: 37,450 shares @ $33.62 each — $1,259,069 paid.
- Sales: total 37,450 shares sold across multiple trades at weighted avg prices (breakdowns reported with ranges: $92.69–$97.34 depending on tranche); aggregate proceeds ≈ $3,578,820.
- 1,800 @ $93.22 (weighted avg for that block)
- 3,128 @ $94.16
- 21,086 @ $95.49
- 11,036 @ $96.43
- 400 @ $97.21
- Footnotes: trades executed under a 10b5-1 trading plan adopted Dec 24, 2025 (F1). Multiple-trade ranges and weighted-average prices are disclosed (F3–F7). Form notes holdings include 54,400 Restricted Stock Units (F2).
- Shares owned after transaction: the exercised shares were sold the same day (no net increase from this exercise); total reported holdings after the transaction are not fully specified in the excerpt beyond the 54,400 RSUs reference.
Context
- This is an exercise-and-sale (option exercise followed by immediate open‑market sales), commonly executed to realize gains or cover exercise costs/taxes; the 10b5‑1 plan indicates the sales were pre‑planned and automated. The derivative line at $0 reflects conversion/settlement reporting conventions for exercised options. The filing appears timely (reported the next day).
Insider Transaction Report
Form 4
Mancini Anthony
See Remarks
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-03-25$33.62/sh+37,450$1,259,069→ 91,850 total - Sale
Common Stock
[F1][F3][F2]2026-03-25$93.22/sh−1,800$167,801→ 90,050 total - Sale
Common Stock
[F1][F4][F2]2026-03-25$94.16/sh−3,128$294,520→ 86,922 total - Sale
Common Stock
[F1][F5][F2]2026-03-25$95.49/sh−21,086$2,013,416→ 65,836 total - Sale
Common Stock
[F1][F6][F2]2026-03-25$96.43/sh−11,036$1,064,200→ 54,800 total - Sale
Common Stock
[F1][F7][F2]2026-03-25$97.21/sh−400$38,883→ 54,400 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F8]2026-03-25−37,450→ 112,350 totalExercise: $33.62Exp: 2035-03-31→ Common Stock (37,450 underlying)
Footnotes (8)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.
- [F2]Includes 54,400 Restricted Stock Units.
- [F3]This transaction was executed in multiple trades at prices ranging from $92.69 to $93.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $93.75 to $94.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $95.00 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $96.00 to $96.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F7]This transaction was executed in multiple trades at prices ranging from $97.12 to $97.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F8]Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Signature
/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini|2026-03-26